LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pen-Like Device for Real Time Tissue Analysis to Revolutionize Surgical Pathology

By LabMedica International staff writers
Posted on 04 May 2023
Print article
Image: The non-invasive pen-like device enables painless tissue analysis (Photo courtesy of MS Pen)
Image: The non-invasive pen-like device enables painless tissue analysis (Photo courtesy of MS Pen)

For over a century, cancer tissue analysis has depended on long-established workflows, with traditional histopathology results typically taking 40 minutes or more. In this process, tissue is biopsied, sent to a lab, frozen, sliced, stained, and examined by a pathologist under a microscope. While awaiting results, the patient remains under anesthesia, increasing their risk of infection and incurring additional costs for both the patient and hospital. Now, a groundbreaking device incorporating cutting-edge mass spectrometry and artificial intelligence (AI) can identify cancerous tissue—in vivo and ex vivo—within just 10 seconds, empowering surgeons, oncologists, and healthcare providers with real-time decision-making capabilities.

The MasSpec Pen System from MS Pen Technologies (Houston, TX, USA) is a proprietary, user-friendly, disposable, and biocompatible device that facilitates rapid tissue analysis. This non-invasive pen-like instrument grants medical professionals access to sophisticated technology that was previously available only to specialists. The MasSpec Pen System ensures fast, precise and highly accurate tissue identification, both in vivo and ex vivo. The more cancer is removed, the less likely tumors will recur and the less likely patients will need adjuvant treatments.

The MasSpec Pen System requires only a small amount of water and three seconds of gentle contact, eliminating the need to destroy or remove healthy tissue. This results in improved precision, recovery periods, and outcomes. Probes from the disposable MasSpec pen connect directly to the mass spectrometer's console, which analyzes the droplet to generate a unique molecular fingerprint of the sample. Advanced data analytics and AI transform complex metabolic data into straightforward, actionable information. Predictive statistical models built from molecular data distinguish between normal and cancerous tissues. In 10 seconds or less, the software provides easily interpretable diagnostic results in real time.

With the MasSpec Pen System, medical professionals can characterize tissues without leaving the operating room or extracting tissue from the patient. This portable, battery-operated machine can be relocated as needed—whether to a patient room or just inches from the operating table. Due to its quick and non-invasive nature, the process can be repeated multiple times if suspicious tissue remains. By eliminating the need for repeated invasive pathology results, the MasSpec Pen System significantly reduces procedure times, decreases extended anesthesia use, lowers the risk of infection, and minimizes financial burdens for both patients and hospital systems.

Related Links:
MS Pen Technologies 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.